Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul-Aug;33(4):931-936.
doi: 10.12669/pjms.334.12571.

Therapeutic benefits of green tea extract on various parameters in non-alcoholic fatty liver disease patients

Mazhar Hussain  1 , Habib-Ur-Rehman  2 , Lubna Akhtar  3
Affiliations

Therapeutic benefits of green tea extract on various parameters in non-alcoholic fatty liver disease patients

Mazhar Hussain et al. Pak J Med Sci. 2017 Jul-Aug.

Abstract

Background and objective: NAFLD affecting up to 30% of the population globally. Drug treatment options are limited with disappointing results. The dietary supplementation in the form of green tea is another option. Our objective was toinvestigate the effect of Green tea extract (GTE) supplementation on various parameters innon-alcoholicfatty liver disease (NAFLD) patients.

Methods: This study was conducted Dept. of Medicineof Sheikh Zayed Medical College/Hospital, Rahim Yar Khan from 15 April 2016 to 15 July 2016. Eighty overweight, non diabeticand dyslipidemic patients of NAFLD, diagnosed on the basis of ultrasound and aminotransferases level were randomized for treatmentwith capsule GTE500mg (n=40)and capsule placebo (n=40) twice a day for twelve weeks. Anthropometric parameters, liver enzymes, inflammatory markers and liver ultrasound imaging were estimated by SPSS-16 pre and post treatment.

Results: As compared to placebo, GTE caused a significant improvement in body weight (29.5±3.8 to 27.2±3.2 kg/m2 p=0.03), BMI (86±10.5 to 80±12.4 kg p=0.026), HOMA-IR(4.32±2.25 to 3.16± 1.6 p=0.0081) lipid profile (i.e. TC: L242.5±20.5 to 215.4±18.6 mg/dl p=0.005; TG: 175±22.6 to145±18 mg/dlp=0.003; LDL-C:155±12.5 to 140±16.7 mg/dl p=0.011; HDL-C: 36.8±6.7 to46.4±5.8 mg/dl p =0.001, Aminotransferases (i.e. ALT: 70.4±15.8to52.8±12.2 IU/L p=0.04; AST: 65.8±12.4 to 44.3± 8.5U/L p =0.002) and Inflammatory markers (hs-CRP: 3.14±0.58 to 2.18±0.32 p =0.023 Adiponectin: 8.46±1.02 to 10.55±3.42μg/ml p =0.003)GTE also caused a 67.5% regression of fatty liver changes on ultrasound as compared to placebo which is 25%only.

Conclusion: GTEtherapy resulted in significant improvement in metabolic, chemical, inflammatory and radiological parameters of non-alcoholic fatty liver disease patients who were non-diabetic anddyslipidemic.

Keywords: Aminotransferases; Dyslipidemia; Green tea extract; Non alcoholic fatty liver disease.

PubMed Disclaimer

Conflict of interest statement

Declaration of interest: None.

References

    1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epideminiology of non alcoholic fatty liver disease- meta-analytic assessment of prevalence, incidence and outcomes. Hepatolgy. 2016;64(1):73–84. doi:10.1002/hep.28431. - PubMed
    1. Ashtaris S, Pourhoseingholi MA, Zali MR. Non alcoholic fatty liver disease in Asia: prevention and planning. World J Hepatol. 2015;7(13):1788–1796. doi:10.4254/wjh.v7.i13.1788. - PMC - PubMed
    1. Milic S, Lulic D, Stimac D. Non alcoholic fatty liver diseaseand obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol. 2014;20(28):9330–9337. doi:10.3748/wjg.v20.i28.9330. - PMC - PubMed
    1. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1):S47–S64. doi:10.16/j.jhep.2014.12.012. - PubMed
    1. Hashimoto E, Tanjgi M, Tokusghige K. Characteristics and diagnosis of NAFLD/NASH. J Gastroenterol Hepatol. 2013;28(4):64–76. doi:10.111/jgh.12271. - PubMed

LinkOut - more resources